Tags

Type your tag names separated by a space and hit enter

Winning a won game: caffeine panacea for obesity syndemic.
Curr Neuropharmacol. 2010 Jun; 8(2):149-60.CN

Abstract

Over the past decades, chronic sleep reduction and a concurrent development of obesity have been recognized as a common problem in the industrialized world. Among its numerous untoward effects, there is a possibility that insomnia is also a major contributor to obesity. This attribution poses a problem for caffeine, an inexpensive, "natural" agent that is purported to improve a number of conditions and is often indicated in a long-term pharmacotherapy in the context of weight management. The present study used the "common target" approach by exploring the tentative shared molecular networks of insomnia and adiposity. It discusses caffeine targets beyond those associated with adenosine signaling machinery, phosphodiesterases, and calcium release channels. Here, we provide a view suggesting that caffeine could exert some of its effects by acting on several signaling complexes composed of HIF-1α/VEGF/IL-8 along with NO, TNF-α, IL1, and GHRH, among others. Although the relevance of these targets to the reported therapeutic effects of caffeine has remained difficult to assess, the utilization of caffeine efficacies and potencies recommend its repurposing for development of novel therapeutic approaches. Among indications mentioned, are neuroprotective, nootropic, antioxidant, proliferative, anti-fibrotic, and anti-angiogenic that appear under a variety of dissimilar diagnostic labels comorbid with obesity. In the absence of safe and efficacious antiobesity agents, caffeine remains an attractive adjuvant.

Authors+Show Affiliations

Howard University Graduate School (Washington, DC). myslobom@mail.nih.govNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21119886

Citation

Myslobodsky, M, and A Eldan. "Winning a Won Game: Caffeine Panacea for Obesity Syndemic." Current Neuropharmacology, vol. 8, no. 2, 2010, pp. 149-60.
Myslobodsky M, Eldan A. Winning a won game: caffeine panacea for obesity syndemic. Curr Neuropharmacol. 2010;8(2):149-60.
Myslobodsky, M., & Eldan, A. (2010). Winning a won game: caffeine panacea for obesity syndemic. Current Neuropharmacology, 8(2), 149-60. https://doi.org/10.2174/157015910791233213
Myslobodsky M, Eldan A. Winning a Won Game: Caffeine Panacea for Obesity Syndemic. Curr Neuropharmacol. 2010;8(2):149-60. PubMed PMID: 21119886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Winning a won game: caffeine panacea for obesity syndemic. AU - Myslobodsky,M, AU - Eldan,A, PY - 2009/11/20/received PY - 2010/02/20/revised PY - 2010/02/23/accepted PY - 2010/12/2/entrez PY - 2010/12/2/pubmed PY - 2010/12/2/medline KW - Caffeine targets KW - networks KW - obesity KW - polypharmacy. KW - reactive oxygen species SP - 149 EP - 60 JF - Current neuropharmacology JO - Curr Neuropharmacol VL - 8 IS - 2 N2 - Over the past decades, chronic sleep reduction and a concurrent development of obesity have been recognized as a common problem in the industrialized world. Among its numerous untoward effects, there is a possibility that insomnia is also a major contributor to obesity. This attribution poses a problem for caffeine, an inexpensive, "natural" agent that is purported to improve a number of conditions and is often indicated in a long-term pharmacotherapy in the context of weight management. The present study used the "common target" approach by exploring the tentative shared molecular networks of insomnia and adiposity. It discusses caffeine targets beyond those associated with adenosine signaling machinery, phosphodiesterases, and calcium release channels. Here, we provide a view suggesting that caffeine could exert some of its effects by acting on several signaling complexes composed of HIF-1α/VEGF/IL-8 along with NO, TNF-α, IL1, and GHRH, among others. Although the relevance of these targets to the reported therapeutic effects of caffeine has remained difficult to assess, the utilization of caffeine efficacies and potencies recommend its repurposing for development of novel therapeutic approaches. Among indications mentioned, are neuroprotective, nootropic, antioxidant, proliferative, anti-fibrotic, and anti-angiogenic that appear under a variety of dissimilar diagnostic labels comorbid with obesity. In the absence of safe and efficacious antiobesity agents, caffeine remains an attractive adjuvant. SN - 1875-6190 UR - https://www.unboundmedicine.com/medline/citation/21119886/Winning_a_won_game:_caffeine_panacea_for_obesity_syndemic_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1570-159X&volume=8&issue=2&spage=149&aulast=Myslobodsky DB - PRIME DP - Unbound Medicine ER -